跳到主要内容

瓦迪姆 S. Koshkin

MD

泌尿系肿瘤
Avid traveler and reader, Chicago sports fan and trivia buff

Dr. 瓦迪姆年代. Koshkin is a genitourinary oncologist who specializes in caring for adults with bladder, 前列腺癌, 肾癌和睾丸癌. His personal enthusiasm for travel informs his approach to care, as he likes to hear about where his patients come from in order to better understand who they are.

在他的研究, Koshkin designs and carries out clinical trials of treatments for bladder and 前列腺癌 cancers. He has a particular focus on the role of immunotherapy, or treatments that stimulate a patient's own immune system to help fight cancer. He also studies targeted treatments that are aimed against specific mutations in the DNA of tumor cells, which make these tumors more vulnerable to particular drugs. This allows for the delivery of personalized treatment based on individual characteristics of patients and their tumors.

After earning his medical degree at the University of Chicago Pritzker School of Medicine, Koshkin completed a residency in internal medicine at the University of Michigan. He then completed a fellowship in hematology and oncology at the Cleveland Clinic. He belongs to the American Society of Clinical Oncology, American Association for Cancer Research and Bladder Cancer Advocacy Network.

A history and trivia buff, Koshkin loves to read. He also follows soccer and Chicago sports teams in his free time.

  • 教育

    University of Chicago Pritzker School of Medicine, 2012

  • 派驻

    University of Michigan, Internal Medicine, 2015

  • 奖学金

    Cleveland Clinic, Hematology/Oncology, 2018

  • 委员会认证

    Internal Medicine, American Board of Internal Medicine

Each cancer patient is unique and deserves unique care. This means extra attention to personal needs but also individualized attention to treatment.

我在那里看病人 (2)

    我的评论

    4.9

    总体经验
    197年评级
    关于我们的流程
    2023年10月5日
    非常有知识,开放,善良和关心
    2023年9月9日
    科什金博士很棒.
    2023年7月28日
    瓦迪姆·科什金是最棒的!
    2023年7月16日
    一如既往的博士. And his Fellow were courteous and professional.
    2023年7月7日
    伟大的工作
    2023年7月2日
    科什金博士在各方面都是一流的!
    2023年6月30日
    对Dr的绝对信心. Koshkin's medical care and concern for patient's well being.
    2023年5月25日
    I don't know what the outcome was of my visit. I need to no what the Good and the bad please.
    2023年4月8日
    干得好
    2023年4月5日
    科什金博士很棒!!
    2023年1月30日
    Dr Koshkin has always been and continues to be a fantastic physician for me. He treated me successfully for my urethral cancer which included 6 months of chemotherapy. 他应该得到尽可能高的分数.
    2023年1月5日
    I have had the very best of attention- from Dr koshkin
    2022年12月23日
    伟大的工作
    2022年10月12日
    伟大的工作
    2022年9月21日
    科什金博士很棒!
    2022年8月23日
    就在最上面
    2022年8月12日
    非常好的十大赌博平台排行榜
    2022年7月15日
    我推荐ucsf
    2022年5月29日
    Dr. Koshkin always makes me feel part of the decision for my treatment. His concern is real and I always feel like he cares.
    2022年5月27日
    优秀的
    2022年5月20日
    科什金博士很棒! 伟大的侦听器
    2022年4月17日
    I couldn't have asked for a better doctor.
    2022年3月16日
    优秀的护理
    装饰墨丘利的节

    Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer ...

    The time from randomization to first documentation of disease progression per RECIST v1.1人死于BICR,或因任何原因死亡.

    招聘

    装饰墨丘利的节

    Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate C...

    If two or more patients in a cohort experience a dose-limiting toxicity (DLT), then the maximum tolerated dose (MTD)has been exceeded. The previous dose level will be considered the MTD and the recommended phase 2 dose. 每一个投资...

    招聘

    装饰墨丘利的节

    A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HE...

    The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1

    招聘

    装饰墨丘利的节

    HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

    The proportion of participants who have a best overall response (BOR) based on complete response (CR) or partial response (PR). The BOR for each participant is the best response (radiographically documented and measurable disease ...

    招聘

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF are covered by every insurance plan.

    分享